Alexza Pharmaceuticals (ALXA +24%) soaring premarket as it resubmits its application for Adasuve, a schizophrenic and bipolar disorder treatment. A previous FDA letter suggested a manufacturing deficiency needed to be resolved, but seemed to flag no other concerns for the drug.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs